Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis

Autor: Irene Maria Ruggeri, Roberta Boemi, Annalisa Speranza, Giuseppe Stefano Calvagno, P M Boemi, Sergio Neri, Bruno Cm, M Valenti, D Ierna, Annalisa Ardiri, Maria Milena Santonocito, Gaetano Bertino, Simona Naimo
Rok vydání: 2010
Předmět:
Male
Hepacivirus
medicine.disease_cause
Gastroenterology
Polyethylene Glycols
Hemoglobins
chemistry.chemical_compound
Eritropoietin
Medicine
Pharmacology (medical)
Longitudinal Studies
Prospective Studies
Anemia
Hypochromic
biology
Epoietin alpha
Peg-interferon
Ribavirin
SVR
QoL
General Medicine
Hepatitis C
Middle Aged
Viral Load
Recombinant Proteins
Treatment Outcome
RNA
Viral
Drug Therapy
Combination
Female
Adult
medicine.medical_specialty
Anemia
Hepatitis C virus
Interferon alpha-2
Antiviral Agents
Drug Administration Schedule
Pharmacotherapy
Internal medicine
Humans
Adverse effect
Erythropoietin
Pharmacology
Hepatitis
business.industry
Interferon-alpha
Hepatitis C
Chronic
biology.organism_classification
medicine.disease
Epoetin Alfa
chemistry
Ferritins
Immunology
Hematinics
Quality of Life
business
Zdroj: European Journal of Clinical Pharmacology. 66:1055-1063
ISSN: 1432-1041
0031-6970
DOI: 10.1007/s00228-010-0868-4
Popis: The conventional antiviral treatment of chronic hepatitis related to hepatitis C virus (HCV) often leads to anemia. In this case, it is necessary to reduce ribavirin dose or stop treatment, thus reducing the rate of sustained virological response. We investigated whether epoetin alpha administration improves treatment adherence and leads to higher percentage of response at the end of therapy and sustained virological response. Two hundred and fourteen individuals with genotype 1b HCV-related chronic hepatitis underwent treatment with pegylated (peg)-interferon alpha-2A 180 μg once weekly and ribavirin 1,000–1,200 mg/day; 174 were responders. Forty individuals completed treatment with no hemoglobin reduction; 134 developed anemia during therapy. Anemic responders were distributed randomly into two groups: group 1 continued therapy with epoetin alpha addiction; group 2 continued antiviral therapy with ribavirin reduction only. Patients in group 1 achieved better control of hemoglobin levels (13.8 ± 1.2 g/dl at the end of therapy) than tthose in group 2 (11.5 ± 0.8 g/dl). Sustained virological response was 59.7% in group 1 compared with 34.4% in group 2 (p
Databáze: OpenAIRE
Externí odkaz: